RecruitingNCT05259605
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Studying Glial tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Michael WellerEORTC Study Coordinator
- Intervention
- Observational(other)
- Enrollment
- 1650 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2038
Study locations (30)
- Innsbruck Universitaetsklinik, Innsbruck, Austria
- Universitaetsklinikum Wien - AKH unikliniken, Vienna, Austria
- Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
- Institut Jules Bordet, Anderlecht, Belgium
- Universitair Ziekenhuis Brussel, Brussels, Belgium
- C.H.U. Sart-Tilman, Liège, Belgium
- AZ Delta - Campus Rumbeke, Roeselare, Belgium
- CHU Lyon - Hopital neurologique Pierre Wertheimer, Lyon, France
- Hopital de La Timone, Marseille, France
- Hopital la Pitie-Salpetriere, Paris, France
- Knappschaft Krankenhaus Langendreer, Bochum, Germany
- Universitaetsklinikum Bonn, Bonn, Germany
- Universitaetsklinikum Koeln, Cologne, Germany
- Universitaetsklinikum - Essen, Essen, Germany
- University Hospital Frankfurt -Senckenberg Institute of Neurooncology, Frankfurt, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05259605 on ClinicalTrials.govOther trials for Glial tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07210632Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)Eben Rosenthal
- RECRUITINGNCT07236840Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain TumorsTata Memorial Centre
- RECRUITINGNCT07240662Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse GliomaiOMEDICO AG
- RECRUITINGNCT07405372Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of GliomasDaping Hospital and the Research Institute of Surgery of the Third Military Medical University
- RECRUITINGPHASE2NCT07110246Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasUniversity of California, San Francisco
- RECRUITINGPHASE1NCT07223034A Study of 177Lu-PSMA-617 in People With GliomasMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGNCT07238322[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related ChangesTelix Pharmaceuticals (Innovations) Pty Limited
- RECRUITINGNANCT06397560PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies TrialBaptist Health South Florida